CNCE · Concert Pharmaceuticals Inc

-

Please sign in to comment on CNCE

1 Comment

Admin

4 years ago

Concert Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 53.0% below its 200 day moving average.

From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.0.

Concert Pharmaceuticals, Inc's total revenue sank by 46.2% to $7K since the same quarter in the previous year.

Its net income has dropped by 9.3% to $-22M since the same quarter in the previous year.

Finally, its free cash flow fell by 6.6% to $-16M since the same quarter in the previous year.

Based on the above factors, Concert Pharmaceuticals, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD
ISIN	US2060221056

Market Cap	402M
Beta	0.52
PE Ratio	None
Target Price	13
Dividend Yield	0.0%

ABOUT

Concert Pharmaceuticals Inc

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of March 6, 2023, Concert Pharmaceuticals, Inc. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

CNCE · Concert Pharmaceuticals Inc

-

Concert Pharmaceuticals Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Concert Pharmaceuticals Inc using a moving average strategy